Tom Frohlich, Jade Biosciences CEO

Q&A: Jade CEO talks about re­verse merg­er and IgAN drugs

This week, biotech builder Paragon Ther­a­peu­tics took two of its port­fo­lio com­pa­nies pub­lic through re­verse merg­ers — Cres­cent Bio­phar­ma and now

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA